Intricon (IIN) 10-Q 8 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Oct. 31, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Registrant Name	INTRICON CORP
Entity Central Index Key	0000088790
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		8,778,963
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	1-5005
Entity Incorporation, State or Country Code	PA
Entity Tax Identification Number	23-1069060
Entity Address, Address Line One	1260 Red Fox Road
Entity Address, City or Town	Arden Hills
Entity Address, Postal Zip Code	55112
Entity Address, State or Province	MN
City Area Code	651
Local Phone Number	636-9770
Title of 12(b) Security	Common stock, par value $1.00 per share
Trading Symbol	IIN
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash, cash equivalents and restricted cash	$ 8,688	$ 8,047
Short-term investments	20,315	38,093
Accounts receivable, less allowance for doubtful accounts of $306 at September 30, 2019 and $807 at December 31, 2018	8,425	11,266
Inventories	17,883	18,163
Contract assets	8,513	5,624
Other current assets	2,290	2,146
Current assets of discontinued operations	239	1,205
Total current assets	66,353	84,544
Machinery and equipment	40,525	36,725
Less: Accumulated depreciation	26,867	25,303
Net machinery and equipment	13,658	11,422
Goodwill	9,551	10,808
Intangible assets, net		2,585
Operating lease right of use assets, net	4,749
Investment in partnerships	1,409	2,091
Long-term investments	13,764
Other assets, net	6,196	3,427
Noncurrent assets of discontinued operations		371
Total assets	115,680	115,248
Current liabilities:
Current financing leases	108
Current operating leases	1,790
Accounts payable	11,407	12,871
Accrued salaries, wages and commissions	3,063	4,409
Other accrued liabilities	4,033	4,031
Liabilities of discontinued operations	393	336
Total current liabilities	20,794	21,647
Noncurrent financing leases	55
Noncurrent operating leases	3,296
Other postretirement benefit obligations	343	377
Accrued pension liabilities	725	706
Other long-term liabilities	1,162	544
Total liabilities	26,375	23,274
Commitments and contingencies
Shareholders' equity:
Common stock, $1.00 par value per share; 20,000 shares authorized; 8,778 and 8,664 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	8,778	8,664
Additional paid-in capital	86,358	84,999
Accumulated deficit	(5,054)	(509)
Accumulated other comprehensive loss	(524)	(927)
Total shareholders' equity	89,558	92,227
Non-controlling interest	(253)	(253)
Total equity	89,305	91,974
Total liabilities and equity	$ 115,680	$ 115,248

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Consolidated Condensed Balance Sheets [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 306	$ 807
Common stock, par value	$ 1	$ 1
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	8,778,000	8,664,000
Common stock, shares outstanding	8,778,000	8,664,000

Consolidated Condensed Statemen

Consolidated Condensed Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Consolidated Condensed Statements Of Operations [Abstract]
Revenue, net	$ 26,893	$ 29,566	$ 85,800	$ 83,590
Cost of goods sold	20,120	20,236	62,253	56,435
Gross profit	6,773	9,330	23,547	27,155
Operating expenses:
Sales and marketing	2,609	2,784	9,071	8,023
General and administrative	3,715	2,921	10,551	8,429
Research and development	840	1,251	2,902	3,693
Impairment loss (Note 10)			3,765
Total operating expenses	7,164	6,956	26,289	20,145
Operating income (loss)	(391)	2,374	(2,742)	7,010
Interest income (expense), net	240	(48)	703	(453)
Other expense, net	(52)	(221)	(458)	(650)
Income (loss) from continuing operations before income taxes and discontinued operations	(203)	2,105	(2,497)	5,907
Income tax expense (benefit)	87	(97)	334	358
Income (loss) from continuing operations before discontinued operations	(290)	2,202	(2,831)	5,549
Loss on disposal of discontinued operations (Note 3)			(1,116)
Loss from discontinued operations, net of income taxes (Note 3)		(299)	(597)	(870)
Net income (loss)	$ (290)	$ 1,903	$ (4,544)	$ 4,679
Basic income (loss) per share:
Continuing operations	$ (0.03)	$ 0.28	$ (0.32)	$ 0.77
Discontinued operations		(0.04)	(0.20)	(0.12)
Net income (loss) per share:	(0.03)	0.24	(0.52)	0.65
Diluted income (loss) per share:
Continuing operations	(0.03)	0.25	(0.32)	0.66
Discontinued operations		(0.03)	(0.20)	(0.10)
Net income (loss) per share:	$ (0.03)	$ 0.22	$ (0.52)	$ 0.56
Average shares outstanding:
Basic	8,764	7,825	8,738	7,249
Diluted	8,764	8,822	8,738	8,360

Consolidated Condensed Statem_2

Consolidated Condensed Statements Of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Consolidated Condensed Statements Of Comprehensive Income (Loss) [Abstract]
Net income (loss)	$ (290)	$ 1,903	$ (4,544)	$ 4,679
Realized foreign currency translation loss from discontinued operations previously unrealized, net of taxes of $0			280
Unrealized foreign currency translation adjustment from continuing operations, net of taxes of $0	9	9	(10)	(171)
Interest rate swap, net of taxes of $0		(4)		(1)
Investment in partnerships, net of taxes of $0			118
Pension and postretirement obligations, net of taxes of $0	5	5	15	15
Comprehensive income (loss)	$ (276)	$ 1,913	$ (4,141)	$ 4,522

Consolidated Condensed Statem_3

Consolidated Condensed Statements Of Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Consolidated Condensed Statements Of Comprehensive Income (Loss) [Abstract]
Realized foreign currency translation loss from discontinued operations previously unrealized, tax			$ 0
Unrealized foreign currency translation adjustment from continuing operations, tax	$ 0	$ 0	0	$ 0
Interest rate swap, tax		0		0
Investment in partnerships, tax			0
Pension and postretirement obligations, tax	$ 0	$ 0	$ 0	$ 0

Consolidated Condensed Statem_4

Consolidated Condensed Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net income (loss)	$ (4,544)	$ 4,679
Loss from discontinued operations, net of tax	1,713	870
Income (loss) from continuing operations	(2,831)	5,549
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Depreciation and amortization	2,448	2,107
Impariment loss	3,765
Equity in loss of partnerships	206	300
Stock-based compensation	1,514	1,025
Change in allowance for doubtful accounts	(501)	368
Changes in operating assets and liabilities:
Accounts receivable	3,394	(5,110)
Inventories	110	(4,856)
Contract assets	(2,889)	(3,345)
Other assets	(165)	(391)
Accounts payable	(1,773)	2,722
Accrued expenses	(1,372)	49
Other liabilities	(123)	(146)
Net cash provided by (used in) operating activities of continuing operations	1,783	(1,728)
Net cash (used in) operating activities of discontinued operations	(24)	(984)
Net cash provided by (used in) operating activities	1,759	(2,712)
Cash flows from investing activities:
Purchases of machinery and equipment	(3,787)	(3,496)
Payments for acquistion of other assets	(696)
Purchase of investment securities	(40,590)
Proceeds from sale of investment securities	38,015
Proceeds from maturities of investment securities	6,425
Investment in partnerships	(296)	(843)
Net cash (used in) investing activities of continuing operations	(929)	(4,339)
Net cash (used in) investing activities of discontinued operations	(16)
Net cash (used in) investing activities	(945)	(4,339)
Cash flows from financing activities:
Proceeds from long-term debt		14,195
Repayments of long-term debt		(25,539)
Proceeds from issuance of common stock, net of costs		88,967
Payments for repurchase of common stock and related costs		(25,907)
Payment of financing leases	(82)
Exercise of stock options and employee stock purchase plan shares	263	584
Withholding of common stock upon vesting of restricted stock units	(304)
Net cash provided by (used in) financing activities	(123)	52,300
Effect of exchange rate changes on cash of continuing operations	(46)	(24)
Effect of exchange rate changes on cash of discontinued operations	(4)	(2)
Effect of exchange rate changes on cash	(50)	(26)
Net increase in cash	641	45,223
Cash, cash equivalents and restricted cash, beginning of period	8,047	1,017
Cash, cash equivalents and restricted cash, end of period	8,688	46,240
Non-cash investing and financing:
Acquisition of machinery and equipment in accounts payable	305	2,098
Investment in partnership through liability incurred		$ 86
Fitting software other asset through liabilities incurred and exchange of investment in partnership	$ 3,093

Consolidated Condensed Statem_5

Consolidated Condensed Statements Of Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings (Accumulated Deficit) [Member]	Accumulated Other Comprehensive Loss [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2017	$ 6,900	$ 21,581	$ (6,056)	$ (733)	$ (253)	$ 21,439
Balance, shares at Dec. 31, 2017	6,900
Exercise of stock options, net	$ 41	167				208
Exercise of stock options, net, shares	41
Shares issued under the employee stock purchase plan	$ 3	57				60
Shares issued under the employee stock purchase plan, shares	3
Stock-based compensation		333				333
Net income (loss)			757			757
Comprehensive income (loss)				86		86
Balance at Mar. 31, 2018	$ 6,944	22,138	(5,299)	(647)	(253)	22,883
Balance, shares at Mar. 31, 2018	6,944
Balance at Dec. 31, 2017	$ 6,900	21,581	(6,056)	(733)	(253)	21,439
Balance, shares at Dec. 31, 2017	6,900
Net income (loss)						4,679
Balance at Sep. 30, 2018	$ 8,640	84,510	(1,404)	(889)	(253)	90,604
Balance, shares at Sep. 30, 2018	8,640
Balance at Mar. 31, 2018	$ 6,944	22,138	(5,299)	(647)	(253)	22,883
Balance, shares at Mar. 31, 2018	6,944
Exercise of stock options, net	$ 92	(37)				55
Exercise of stock options, net, shares	92
Shares issued under the employee stock purchase plan	$ 1	54				55
Shares issued under the employee stock purchase plan, shares	1
Stock-based compensation		334				334
Net income			1,992			1,992
Comprehensive income (loss)				(252)		(252)
Balance at Jun. 30, 2018	$ 7,037	22,489	(3,307)	(899)	(253)	25,067
Balance, shares at Jun. 30, 2018	7,037
Exercise of stock options, net	$ 377	(227)				150
Exercise of stock options, net, shares	377
Shares issued under the employee stock purchase plan	$ 1	55				56
Shares issued under the employee stock purchase plan, shares	1
Withholding of common stock upon vesting of restricted stock units	$ 1,725	87,242				88,967
Withholding of common stock upon vesting of restricted stock units, shares	1,725
Repurchase of common stock	$ (500)	(25,407)				(25,907)
Repurchase of common stock, shares	(500)
Stock-based compensation		358				358
Net income (loss)			1,903			1,903
Comprehensive income (loss)				10		10
Balance at Sep. 30, 2018	$ 8,640	84,510	(1,404)	(889)	(253)	90,604
Balance, shares at Sep. 30, 2018	8,640
Balance at Dec. 31, 2018	$ 8,664	84,999	(509)	(927)	(253)	91,974
Balance, shares at Dec. 31, 2018	8,664
Exercise of stock options, net	$ 27	(9)				18
Exercise of stock options, net, shares	27
Shares issued under the employee stock purchase plan	$ 3	67				70
Shares issued under the employee stock purchase plan, shares	3
Withholding of common stock upon vesting of restricted stock units	$ 20
Withholding of common stock upon vesting of restricted stock units		(255)				(235)
Withholding of common stock upon vesting of restricted stock units, shares	20
Stock-based compensation		329				329
Net income (loss)			775			775
Comprehensive income (loss)				130		130
Balance at Mar. 31, 2019	$ 8,714	85,131	266	(797)	(253)	93,061
Balance, shares at Mar. 31, 2019	8,714
Balance at Dec. 31, 2018	$ 8,664	84,999	(509)	(927)	(253)	$ 91,974
Balance, shares at Dec. 31, 2018	8,664
Exercise of stock options, net, shares						128
Net income (loss)						$ (4,544)
Balance at Sep. 30, 2019	$ 8,778	86,358	(5,054)	(524)	(253)	89,305
Balance, shares at Sep. 30, 2019	8,778
Balance at Mar. 31, 2019	$ 8,714	85,131	266	(797)	(253)	93,061
Balance, shares at Mar. 31, 2019	8,714
Exercise of stock options, net	$ 29	22				51
Exercise of stock options, net, shares	29
Shares issued under the employee stock purchase plan	$ 2	48				50
Shares issued under the employee stock purchase plan, shares	2
Withholding of common stock upon vesting of restricted stock units	$ 6
Withholding of common stock upon vesting of restricted stock units		(6)
Withholding of common stock upon vesting of restricted stock units, shares	6
Stock-based compensation	$ 3	534				537
Stock-based compensation, shares	3
Net income (loss)			(5,030)			(5,030)
Comprehensive income (loss)				259		259
Balance at Jun. 30, 2019	$ 8,754	85,729	(4,764)	(538)	(253)	88,928
Balance, shares at Jun. 30, 2019	8,754
Exercise of stock options, net	$ 12	16				28
Exercise of stock options, net, shares	12
Shares issued under the employee stock purchase plan	$ 2	44				46
Shares issued under the employee stock purchase plan, shares	2
Withholding of common stock upon vesting of restricted stock units	$ 10
Withholding of common stock upon vesting of restricted stock units		(79)				(69)
Withholding of common stock upon vesting of restricted stock units, shares	10
Stock-based compensation		648				648
Net income (loss)			(290)			(290)
Comprehensive income (loss)				14		14
Balance at Sep. 30, 2019	$ 8,778	$ 86,358	$ (5,054)	$ (524)	$ (253)	$ 89,305
Balance, shares at Sep. 30, 2019	8,778

General

General	9 Months Ended
	Sep. 30, 2019
General [Abstract]
General	1. General  In the opinion of management, the accompanying consolidated condensed financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly IntriCon Corporation's (“IntriCon” or the “Company”) consolidated financial position as of September 30, 2019 and December 31, 2018, the consolidated results of its operations for the three and nine months ended September 30, 2019 and 2018 and the consolidated statements of equity and cash flows for the nine months ended September 30, 2019 and 2018. Results of operations for the interim periods are not necessarily indicative of the results of operations expected for the full year or any other interim period. These consolidated condensed financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our 2018 Annual Report on Form 10-K filed with the SEC.  On June 25, 2019, the Company’s officers, pursuant to delegated authority from the board, approved plans to discontinue the operations of its United Kingdom (UK) subsidiary within our body worn device segment. For all periods presented, the Company classified this business as discontinued operations, and accordingly, has reclassified historical financial data presented herein. See Note 3.  The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The Company evaluates its voting and variable interests in entities on a qualitative and quantitative basis. The Company consolidates entities in which it concludes it has the power to direct the activities that most significantly impact an entity’s economic success and has the obligation to absorb losses or the right to receive benefits that could be significant to the entity.  The Company has evaluated subsequent events occurring after the date of the consolidated financial statements for events requiring recording or disclosure in the consolidated financial statements.

Changes In Accounting Policies

Changes In Accounting Policies	9 Months Ended
	Sep. 30, 2019
Changes In Accounting Policies [Abstract]
Changes In Accounting Policies	2. Changes in Accounting Policies    The Company’s significant accounting policies are detailed in “Note 1: Summary of Significant Accounting Policies” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. In February 2016, the FASB issued ASU 2016-02 “Leases” (Topic 842). Topic 842 supersedes the lease accounting guidance previously set forth in the Accounting Standards Codification (ASC) Topic 840 “Leases,” and requires lessees to recognize a lease liability and a right-of-use asset (ROU) for all leases that extend beyond one year. The Company adopted Topic 842 with a date of initial application of January 1, 2019, which resulted in a ROU asset and lease liability of approximately $6.0 M. The Company did not apply Topic 842 retrospectively using the transition option in ASU 2018-11, “ Targeted Improvements” to ASC 842, to not restate comparative periods in transition and instead to use the effective date of ASC 842, “Leases”, as the date of initial application of transition. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard which allowed us to carry forward the historical lease classification.  Changes to the Company’s accounting policies as a result of adopting Topic 842 are discussed below:  Short-term lease recognition exemption. The Company adopted the short-term lease recognition exemption as an accounting policy. Accordingly, the Company will not recognize a lease liability and ROU asset for short-term leases in transition and, post-effective date, will continue to recognize short-term leases as expense on a straight-line basis over the lease term. Renewal and purchase options for a lease will be reassessed upon the occurrence of certain discrete reassessment events: (1) the lease term is extended more than 12 months beyond the end of the previously determined lease term or (2) the lessee now concludes that the lessee’s exercise of a purchase option is reasonably certain. When a lease no longer qualifies for the short-term lease exemption, the Company will apply ASC 842 guidance on initial recognition and measurement; the commencement date of the lease for this purpose is the date of the change in circumstances.  Accounting for certain leases at a portfolio level . The Company accounts for leases at a portfolio level when the criteria described below are met and it reasonably expects that the application of the lease model to the portfolio will not differ materially from the application to the individual leases in that portfolio. If the applicable criteria are met, the start of the lease term is expected to be the first of the month. The criteria are: 1. Leases are similar in nature (e.g. similar underlying asset such as vehicles); 2. Leases have identical or nearly identical contract provisions, including same lessor; and 3. Leases with effective dates that fall within a narrow window of time (month or quarter) and have the same lease term.  For purposes of arriving at the transition adjustment on the effective date, a total of seven vehicle leases were combined into three portfolios.  Combining lease and non-lease components into a single component. The Company elected to adopt this practical expedient for all asset classes. As a result of this election, the consideration included in the lease payments for these asset classes will be greater, resulting in a larger lease liability and ROU asset.  

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2019
Discontinued Operations [Abstract]
Discontinued Operations	3. Discontinued Operations On June 25, 2019, the Company’s officers, pursuant to delegated authority from the board, approved plans to discontinue the operations of its UK subsidiary within the body worn device segment. As of September 30, 2019, we continue to settle the remaining assets and liabilities of the subsidiary. The final closing of the UK subsidiary is expected to occur during the fourth quarter of 2019 .  At June 30, 2019, the net realizable value of certain assets was less than their carrying value resulting in a loss on disposal of $1. 0 M . There were no further adjustments made to the net realizable value of assets during the period ended September 30, 2019.  As the disposal meets the definition of a strategic shift in accordance with ASC 205, the results of the UK operations have been classified as loss on discontinued operations, net of income taxes, in the accompanying Consolidated Condensed Statements of Operations, Comprehensive Income (Loss) and Cash Flows. Current assets, noncurrent assets, and liabilities of the discontinued operations have been reclassified and reflected on the accompanying Consolidated Condensed Balance Sheets as “Current assets of discontinued operations,” “Noncurrent assets of discontinued operations,” and “Liabilities of discontinued operations”, respectively. Prior periods relating to our discontinued operations have also been reclassified to reflect consistency within our condensed consolidated financial statements.  The total assets and liabilities of the UK subsidiary at September 30, 2019 and December 31, 2018 were as follows:      September 30, December 31,  2019 2018  Accounts receivable, net $ 1 $ 213  Inventories 21 818  Other current assets 217 174  Current assets of discontinued operations 239 1,205   Machinery and equipment - 436  Less: Accumulated depreciation - 126  Net machinery and equipment - 310   Other assets, net - 61  Total assets $ 239 $ 1,576   Accounts payable - 320  Other accrued liabilities 393 16  Current liabilities of discontinued operations 393 336  Net assets (liabilities) $ (154) $ 1,240  The loss on disposal of discontinued operations, as a result of the plan to discontinue the operations of the UK, for the nine months ended September 30, 2019 was computed as follows:     Cash and cash equivalents $ 5  Accounts receivable, net 72  Write-down of inventory to net realizable value 278  Write-down of property, plant and equipment to salvage value 298  Other assets and liabilities, net 71  Realized loss on foreign currency 280  Net assets disposed 1,004  Additional disposal costs, net 112  Loss on disposal of discontinued operations $ 1,116  The following table shows the results of the UK subsidiary’s discontinued operations:     Three Months Ended Nine Months Ended  September 30, 2019 September 30, 2018 September 30, 2019 September 30, 2018  Revenue, net $ - $ 568 $ 1,068 $ 2,067  Cost of goods sold - 373 667 1,296  Gross profit - 195 401 771  Sales and marketing - 225 314 706  General and administrative - 311 684 1,005  Total operating expenses - 536 998 1,711  Other income, net - 42 - 70  Loss from discontinued operations, net of taxes $ - $ (299) $ (597) $ (870) 

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Segment Reporting	4. Segment Reporting  The Company currently operates in two reportable segments: body-worn devices and hearing health direct-to-end-consumer (DTEC). The nature of distribution and services has been deemed separately identifiable. Therefore, segment reporting has been applied. The following table summarizes certain data from continuing operations by industry segment:      For the Three Months Ended September 30, 2019 Body Worn Devices Hearing Health DTEC Total  Revenue, net $ 25,383 $ 1,510 $ 26,893  Income (loss) from continuing operations before income taxes and discontinued operations 750 (953) (203)  Depreciation and amortization 712 108 820  Capital expenditures 1,374 54 1,428   For the Nine Months Ended September 30, 2019 Body Worn Devices Hearing Health DTEC Total  Revenue, net $ 80,924 $ 4,876 $ 85,800  Impairment loss - (3,765) (3,765)  Income (loss) from continuing operations before income taxes and discontinued operations 5,106 (7,603) (2,497)  Depreciation and amortization 2,210 238 2,448  Capital expenditures 3,651 136 3,787       For the Three Months Ended September 30, 2018 Body Worn Devices Hearing Health DTEC Total  Revenue, net $ 28,076 $ 1,490 $ 29,566  Income (loss) from continuing operations before income taxes and discontinued operations 3,146 (1,041) 2,105  Depreciation and amortization 642 55 697  Capital expenditures 1,884 4 1,888   For the Nine Months Ended September 30, 2018 Body Worn Devices Hearing Health DTEC Total  Revenue, net $ 78,263 $ 5,327 $ 83,590  Income (loss) from continuing operations before income taxes and discontinued operations 7,899 (1,992) 5,907  Depreciation and amortization 1,952 155 2,107  Capital expenditures 3,426 70 3,496   The following table summarizes the identifiable assets (excluding goodwill) and goodwill by industry segment as of the following dates :      September 30, December 31,  2019 2018  Body Worn Devices:  Identifiable assets (excluding goodwill) $ 103,158 $ 97,725  Goodwill 9,551 9,551  Hearing Health DTEC:  Identifiable assets (excluding goodwill) 2,732 5,139  Goodwill - 1,257 

Geographic Information

Geographic Information	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Geographic Information	5. Geographic Information  The geographical distribution of long-lived assets to geographical areas consisted of the following at:     September 30, December 31,  2019 2018  United States $ 12,264 $ 10,065  Singapore 1,311 1,240  Other 83 117  Consolidated $ 13,658 $ 11,422    Long-lived assets consist of machinery and equipment. Excluded from long-lived assets are investments in partnerships, patents, goodwill, operating lease ROU assets and certain other assets. The Company capitalizes long-lived assets pertaining to the production of specialized parts. These assets are periodically reviewed to ensure the net realizable value from the estimated future production based on forecasted cash flows exceeds the carrying value of the assets.  The geographical distribution of net revenue to geographical areas for the three and nine months ended September 30, 2019 and 2018 were as follows:         Three Months Ended Nine Months Ended  Net Revenue to Geographical Areas September 30, 2019 September 30, 2018 September 30, 2019 September 30, 2018  United States $ 22,483 $ 25,157 $ 71,059 $ 70,871  Europe 1,248 1,500 4,480 4,163  Asia 2,780 2,472 9,508 7,639  All other countries 382 437 753 917  Consolidated $ 26,893 $ 29,566 $ 85,800 $ 83,590  Geographic net revenue is allocated based on the location of the customer. For the three and nine months ended September 30, 2019 , one customer accounted for 59% of the Company’s consolidated net revenue. For the three and nine months ended September 30, 2018, one customer accounted for 56% and 57% , respectively, of the Company’s consolidated net revenue. Two customers combined accounted for 43% and 52% of the Company’s consolidated accounts receivable at September 30, 2019 and December 31, 2018, respectively. One customer accounted for 84% and 78% of the Company’s consolidated contract assets at September 30, 2019 and December 31, 2018, respectively.

Investment In Partnerships

Investment In Partnerships	9 Months Ended
	Sep. 30, 2019
Investment In Partnerships [Abstract]
Investment In Partnerships	6. Investment in Partnerships  Investment in partnerships consisted of the following:       September 30, December 31,  2019 2018  Investment in Signison $ 1,246 $ 865  Investment in and cash advance for Soundperience - 1,022  Other 163 204  Total $ 1,409 $ 2,091   The Company has a 50% ownership interest in Signison as of September 30, 2019. Signison is accounted for in the Company’s consolidated financial statements using the equity method. As of December 31, 2018, the Company held a 49% ownership interest in Soundperience, which was accounted for using the equity method. In January 2019, the Company purchased the source code for the Sentibo Smart Brain self-fitting software from Soundperience in exchange for 1,750 Euros, our 49% ownership in Soundperience and the related license agreement. See Note 9.

Investment Securities

Investment Securities	9 Months Ended
	Sep. 30, 2019
Investments Securities [Abstract]
Investment Securities	7. Investment Securities  The Company currently invests in commercial paper, US government agencies and corporate notes and bonds with original maturities of not more than two years. The Company classifies these investments as held to maturity based on our intent and ability to hold these investments until maturity. As a result, these investments are recorded at amortized cost, which approximates fair value as of September 30, 2019. As of December 31, 2018, the Company invested in certain liquid investment securities which were classified as available for sale investments and measured at fair value based on Level 1 inputs.     The maturity dates of our investments as of September 30, 2019 are as follows:  Less than one year 1-5 years Total  Commercial Paper Original Maturities of 91 Days or More $ 6,824 $ - $ 6,824  US Government Agencies - 1,900 1,900  Corporate Notes and Bonds 13,491 11,864 25,355  Total Investments $ 20,315 $ 13,764 $ 34,079 

Inventories

Inventories	9 Months Ended
	Sep. 30, 2019
Inventories [Abstract]
Inventories	8. Inventories Inventories consisted of the following at:     Raw materials Work-in process Finished products and components Total  September 30, 2019  Domestic $ 11,579 $ 3,103 $ 405 $ 15,087  Foreign 2,315 368 113 2,796  Total $ 13,894 $ 3,471 $ 518 $ 17,883   December 31, 2018  Domestic $ 10,657 $ 2,484 $ 1,583 $ 14,724  Foreign 2,671 653 115 3,439  Total $ 13,328 $ 3,137 $ 1,698 $ 18,163 

Other Assets, Net

Other Assets, Net	9 Months Ended
	Sep. 30, 2019
Other Assets, Net [Abstract]
Other Assets, Net	   9. Other Assets, Net  Other assets, net consisted of the following at:     September 30, December 31,  2019 2018  Fitting Software $ 3,679 $ -  NXP Tech 1,964 2,259  Other 553 1,168  Total $ 6,196 $ 3,427   In January 2019, the Company purchased the source code for self-fitting software from Soundperience for 1,750 Euros and also transferred our 49% ownership interest in Soundperience to the majority owner, positioning the Company to capitalize on the upcoming over-the-counter (OTC) hearing aid regulations. The Company has capitalized the self-fitting software within other assets, net based on the cost of the consideration transferred and will begin amortizing the asset when it is placed into service. Included in the capitalized cost of the self-fitting software is $586 of cash paid at closing as well as non-cash amounts of $869 due in future quarterly installments over the next four years, $533 due in January 2023 and $1,691 for the value of the partnership and license agreement transferred. The future payments are due in Euros and the related liabilities will be revalued based on exchange rates as of each reporting period. As of September 30, 2019, outstanding liabilities are $1,260 .

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets [Abstract]
Goodwill and Intangible Assets	10. Goodwill and Intangible Assets  As of and for the period ended June 30, 2019, the fair value of the goodwill within our Hearing Help Express reporting unit was less than its carrying amount and resulted in a non-cash impairment charge on goodwill of $1 ,257 and intangible assets of $2 , 5 08 . There were no further adjustments made to the carrying amount of goodwill and intangible assets as of September 30, 2019.  The following summarizes the consolidated carrying amount of goodwill by period:     Carrying amount at December 31, 2018 $ 10,808  Impairment of goodwill of Hearing Help Express (1,257)  Carrying amount at September 30, 2019 $ 9,551     The following summarizes the consolidated carrying amounts of intangible assets by period:       Carrying amount at December 31, 2018 $ 2,585  Amortization of intangible assets of Hearing Help Express (77)  Impairment of intangible assets of Hearing Help Express (2,508)  Carrying amount at September 30, 2019 $ - 

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	  11. Leases  The Company’s leases pertain primarily to engineering, manufacturing, sales and administrative facilities, with an initial term of one year or more. The Company has three leased facilities in Minnesota, two that expire in 2022 and one that expires in 2023, one leased facility in Illinois that expires in 2021, one leased facility in Singapore that expires in 2020, one leased facility in Indonesia that expires in 2024, and one leased facility in Germany that expires in 2022.  Certain foreign leases allow for variable lease payments that depend on an index or a market rate adjustment for the respective country and are adjusted on an annual basis. The adjustment is recognized as incurred in profit and loss. The facility leases include options to extend for terms ranging from one to five years. Lease options that the Company is reasonably certain to execute, are included in the determination of the ROU asset and lease liability. Our Indonesia lease includes embedded forward starting leases that will begin in 2022 and 2024 for additional square footage, which will result in the recognition of an additional ROU asset and lease liability in those periods of approximately $103 and $72 , respectively. The Company also leases various computer equipment that include bargain purchase options at termination. These leases have been classified as finance leases.  As of September 30, 2019, the Company has a weighted-average lease term of 1.6 years for its finance leases, and 3.3 years for its operating leases. As of September 30, 2019, the Company has a weighted-average discount rate of 5.56% for its finance leases, and 5.25% for its operating leases. Operating cash flows from continuing operations for the nine months ended September 30, 2019 from operating leases were $1,406 . Operating cash flows from discontinued operations for the nine months ended September 30, 2019 from operating leases were $84 . Non-cash increases for the nine months ended September 30, 2019, to the operating lease ROU assets, lease incentive other assets and lease liabilities from continuing operations were $772 , $150 , and $922 , respectively. During the nine months ended September 30, 2019, we derecognized approximately $761 of non-cash operating lease ROU assets and liabilities from our discontinued operations. Financing lease assets are classified as machinery and equipment within the consolidated balance sheet. Short term leases are not significant.  The following tables summarizes lease costs by type:       Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019  Lease cost  Finance lease cost:  Amortization of right-of-use assets $ 27 $ 76  Interest on lease liabilities 3 8   Operating lease cost* 462 1,379  Variable lease cost** 138 417  Total lease cost $ 630 $ 1,880   *Operating lease cost excludes $0 and $86 related to discontinued operations of the UK for the three and nine months ended September 30, 2019, respectively.  **Variable lease costs consist primarily of taxes, insurance, and common area or other maintenance costs for our domestic and foreign building leases, excluding approximately $0 and $11 related to discontinued operations of the UK for the three and nine months ended September 30, 2019, respectively.  Maturities of lease liabilities are as follows:     Operating Leases Financing Leases Total  2019 $ 503 $ 29 $ 532  2020 1,919 105 2,024  2021 1,588 31 1,619  2022 1,023 3 1,026  2023 416 - 416  2024 and thereafter 93 - 93  Total lease payments 5,542 168 5,710  Less: Interest (456) (5) (461)  Present value of lease liabilities $ 5,086 $ 163 $ 5,249   As previously disclosed in Note 20 of the Notes to the Consolidated Financial Statements in our 2018 Annual Report on Form 10-K, prior to the adoption of ASU 2016-02, Leases (Topic 842) , the future minimum payments required under lease agreements as of December 31, 2018 were 2019 - $2,417 ; 2020 - $2,255 ; 2021 - $1,689 ; 2022 - $950 ; 2023 - $188 .

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2019
Income Taxes [Abstract]
Income Taxes	12. Income Taxes  Income tax expense (benefit) for the three and nine months ended September 30, 2019 was $87 and $334 compared to ($97) and $358 for the same period in 2018. The expense was largely due to our foreign operations. The Company has net operating loss carryforwards for U.S. federal income tax purposes. Due to the new tax legislation, there are limitations on the use of certain of the carryforwards. The Company has recorded a full valuation allowance against the deferred tax asset as of September 30, 2019.  The following was the income (loss) from continuing operations before income taxes and discontinued operations for each jurisdiction in which the Company has operations for the three and nine months ended September 30, 2019 and 2018.     Three Months Ended Nine Months Ended  September 30, 2019 September 30, 2018 September 30, 2019 September 30, 2018  United States $ (261) $ 1,575 $ (3,015) $ 4,876  Singapore (90) 378 131 724  Indonesia 18 18 58 60  Germany 130 134 329 247  Income (loss) from continuing operations before income taxes and discontinued operations $ (203) $ 2,105 $ (2,497) $ 5,907   The Company expects impairment losses to be an adjustment to the net loss for the three and nine months ended September 30, 2019 for income tax purposes.

Shareholders' Equity And Stock-

Shareholders' Equity And Stock-Based Compensation	9 Months Ended
	Sep. 30, 2019
Shareholders' Equity And Stock-Based Compensation [Abstract]
Shareholders' Equity And Stock-Based Compensation	13. Shareholders’ Equity and Stock-based Compensation  The Company has a 2006 Equity Incentive Plan and a 2015 Equity Incentive Plan. The 2015 Equity Incentive Plan replaced the 2006 Equity Incentive Plan and new grants may not be made under the 2006 Plan. Under the 2015 Equity Incentive Plan, the Company may grant stock options, stock awards, stock appreciation rights, restricted stock units (“RSUs”) and other equity-based awards. Under all awards, the terms are fixed on the grant date.  The Company granted 4 and 79 RSUs for the three and nine months ended September 30, 2019 , respectively . The weighted average closing price of the Company’s common stock on the date of grant was $19.19 and $23.83 , respectively, for the RSUs granted in the three and nine months ended September 30, 2019. The RSUs vest in equal, annual installments over a three year period beginning on the first anniversary of the date of grant at which time common stock is issued with respect to vested units.  The Company has also granted stock options under the plans. Options granted under the plans generally vest in equal, annual installments over a three year period beginning on the first anniversary of the date of grant and have a maximum term of 10 years.  Stock award activity as of and during the nine months ended September 30, 2019 was as follows:      Outstanding Awards Stock Option Weighted-Average Exercise Price (a) Aggregate Intrinsic Value  Stock Options RSUs Total   Outstanding at December 31, 2018 830 98 928 $ 6.25  Forfeited, cancelled or expired (3) - (3) 6.42  Granted - 79 79 -  Exercised or vested (79) (49) (128) 4.87   Outstanding at September 30, 2019 748 128 876 $ 6.39 $ 12,241   Exercisable at September 30, 2019 670 - 670 $ 6.30 $ 8,799   Available for future grant at December 31, 2018 249   Available for future grant at September 30, 2019 183   (a) The weighted average exercise price calculation does not include outstanding RSUs  The number of shares available for future grants at September 30, 2019 does not include a total of up to 369 shares subject to options outstanding under the 2006 Equity Incentive Plan, which will become available for grant under the 2015 Equity Incentive Plan as outstanding options under the 2006 Equity Incentive Plan expire, terminate, are cancelled or forfeited or are withheld in a net exercise of such options.  The Company recorded $648 and $1,514 of non-cash stock compensation expense for the three and nine months ended September 30, 2019, respectively. The Company recorded $358 and $1,025 of non-cash stock compensation expense for the three and nine months ended September 30, 2018, respectively. As of September 30, 2019, there was $2,321 of total unrecognized compensation costs related to non-vested stock option and RSU awards that are expected to be recognized over a weighted-average period of 1.99 years. The total intrinsic value of options exercised during the three and nine months ended September 30, 2019 was $196 and $1,609 , respectively.  The Company also has an Employee Stock Purchase Plan (the “Purchase Plan”). The Purchase Plan, as amended, through September 30, 2019, provides that a maximum of 300 shares may be sold under the Purchase Plan. There were 2 and 7 shares purchased under the plan for the three and nine months ended September 30, 2019, respectively, and a total of 1 and 5 shares purchased for the three and nine months ended September 30, 2018, respectively.

Income Per Share

Income Per Share	9 Months Ended
	Sep. 30, 2019
Income Per Share [Abstract]
Income Per Share	14. Income Per Share  The following table presents a reconciliation between basic and diluted earnings per share:          Three Months Ended Nine Months Ended  September 30, 2019 September 30, 2018 September 30, 2019 September 30, 2018  Numerator:  Income (loss) from continuing operations before discontinued operations $ (290) $ 2,202 $ (2,831) $ 5,549  Loss on disposal of discontinued operations (Note 3) - - (1,116) -  Loss from discontinued operations, net of income taxes (Note 3) - (299) (597) (870)  Net income (loss) $ (290) $ 1,903 $ (4,544) $ 4,679   Denominator:  Basic – weighted shares outstanding 8,764 7,825 8,738 7,249  Weighted shares assumed upon exercise of stock awards - 997 - 1,111  Diluted – weighted shares outstanding 8,764 8,822 8,738 8,360   Basic income (loss) per share attributable to IntriCon shareholders:  Continuing operations $ (0.03) $ 0.28 $ (0.32) $ 0.77  Discontinued operations - (0.04) (0.20) (0.12)  Net income (loss) per share: $ (0.03) $ 0.24 $ (0.52) $ 0.65   Diluted income (loss) per share attributable to IntriCon shareholders:  Continuing operations $ (0.03) $ 0.25 $ (0.32) $ 0.66  Discontinued operations - (0.03) (0.20) (0.10)  Net income (loss) per share: $ (0.03) $ 0.22 $ (0.52) $ 0.56   The dilutive impact summarized above relates to the periods when the average market price of Company stock exceeded the exercise price of the potentially dilutive options. Earnings per common share was based on the weighted average number of common shares outstanding during the periods when computing the basic earnings per share. When dilutive, stock options are included as equivalents using the treasury stock method when computing the diluted earnings per share. Shares represented by RSUs are also included in the dilution calculation. Individual components of basic and diluted income per share may not sum to the total income per share due to rounding.  For the three and nine months ended September 30, 2019, weighted average options and RSU’s outstanding of 755 and 125 , and 778 and 125 were excluded from the dilutive calculation, respectively, as their effect would have been antidilutive based on losses in the period.

Legal Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2019
Legal Proceedings [Abstract]
Legal Proceedings	15. Legal Proceedings  The Company is a defendant along with a number of other parties in lawsuits alleging that plaintiffs have or may have contracted asbestos-related diseases as a result of exposure to asbestos products or equipment containing asbestos sold by one or more named defendants. These lawsuits relate to the discontinued heat technologies segment which was sold in March 2005. Due to the non-informative nature of the complaints, the Company does not know whether any of the complaints state valid claims against the Company. Certain insurance carriers have informed the Company that the primary policies for the period August 1, 1970-1978 have been exhausted and that the carriers will no longer provide defense and insurance coverage under those policies. However, the Company has other primary and excess insurance policies that the Company believes afford coverage for later years. Some of these other primary insurers have accepted defense and insurance coverage for these suits, and some of them have either ignored the Company’s tender of defense of these cases, or have denied coverage, or have accepted the tenders but asserted a reservation of rights and/or advised the Company that they need to investigate further. Because settlement payments are applied to all years a litigant was deemed to have been exposed to asbestos, the Company believes that it will have funds available for defense and insurance coverage under the non-exhausted primary and excess insurance policies. However, unlike the older policies, the more recent policies have deductible amounts for defense and settlements costs that the Company will be required to pay; accordingly, the Company expects that its litigation costs will increase in the future. Further, many of the policies covering later years (approximately 1984 and thereafter) have exclusions for any asbestos products or operations, and thus do not provide insurance coverage for asbestos-related lawsuits. The Company does not believe that the asserted exhaustion of some of the primary insurance coverage for the 1970-1978 period will have a material adverse effect on its financial condition, liquidity, or results of operations. Management believes that the number of insurance carriers involved in the defense of the suits, and the significant number of policy years and policy limits under which these insurance carriers are insuring the Company, make the ultimate disposition of these lawsuits not material to the Company's consolidated financial position or results of operations.  The Company is also involved in other lawsuits arising in the normal course of business. While it is not possible to predict with certainty the outcome of these matters, management is of the opinion that the disposition of these lawsuits and claims will not materially affect our consolidated financial position, liquidity or results of operations. 

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2019
Related-Party Transactions [Abstract]
Related-Party Transactions	16. Related-Party Transactions  The Company uses the law firm of Blank Rome LLP for legal services. A partner of that firm is the son-in-law of the Chairman of the Company’s Board of Directors, however, on May 1, 2019, the Chairman retired from the Company’s Board of Directors. For the three and nine months ended September 30, 2019 , the Company paid that firm approximately $ 63 and $169 for legal services and costs. For the three and nine months ended September 30, 2018, the Company paid that firm approximately $238 and $413 , respectively, for legal services and costs. The prior Chairman of our Board of Directors was considered independent under applicable Nasdaq and Securities and Exchange Commission rules because (i) no payments were made to the Chairman or the partner directly in exchange for the services provided by the law firm and (ii) the amounts paid to the law firm did not exceed the thresholds contained in the Nasdaq standards. Furthermore, the aforementioned partner does not provide any legal services to the Company and is not involved in billing matters. In January 2019, the Company purchased the source code for the Sentibo Smart Brain self-fitting software from Soundperience, an entity in which we owned 49% of the equity , for 1,750 Euros and the transfer back of our 49% ownership interest in Soundperience. See Note 9.

Revenue By Market

Revenue By Market	9 Months Ended
	Sep. 30, 2019
Revenue By Market [Abstract]
Revenue By Market	17. Revenue by Market  The following tables set forth, for the periods indicated, timing of revenue recognition by market:    Timing of revenue recognition for the three months ended September 30, 2019:  Products and services transferred at point in time Products and services transferred over time Total  Medical Biotelemetry:  Diabetes $ - $ 15,723 $ 15,723  Other Medical - 3,376 3,376  Hearing Health:  Value Based DTEC 1,510 - 1,510  Value Based ITEC 2,443 - 2,443  Legacy OEM 2,405 - 2,405  Professional Audio Communications: 1,436 - 1,436  Total Net Revenue $ 7,794 $ 19,099 $ 26,893   Timing of revenue recognition for the nine months ended September 30, 2019:   Products and services transferred at point in time Products and services transferred over time Total  Medical Biotelemetry:  Diabetes $ - $ 50,837 $ 50,837  Other Medical - 9,947 9,947  Hearing Health:  Value Based DTEC 4,876 - 4,876  Value Based ITEC 7,419 - 7,419  Legacy OEM 7,749 - 7,749  Professional Audio Communications: 4,972 - 4,972  Total Net Revenue $ 25,016 $ 60,784 $ 85,800   Timing of revenue recognition for the three months ended September 30, 2018:   Products and services transferred at point in time Products and services transferred over time Total  Medical Biotelemetry:  Diabetes $ - $ 16,662 $ 16,662  Other Medical - 2,694 2,694  Hearing Health:  Value Based DTEC 1,490 - 1,490  Value Based ITEC 3,660 - 3,660  Legacy OEM 3,056 - 3,056  Professional Audio Communications: 2,004 - 2,004  Total Net Revenue $ 10,210 $ 19,356 $ 29,566   Timing of revenue recognition for the nine months ended September 30, 2018:   Products and services transferred at point in time Products and services transferred over time Total  Medical Biotelemetry:  Diabetes $ - $ 47,531 $ 47,531  Other Medical - 7,956 7,956  Hearing Health:  Value Based DTEC 5,327 - 5,327  Value Based ITEC 8,923 - 8,923  Legacy OEM 8,500 - 8,500  Professional Audio Communications: 5,353 - 5,353  Total Net Revenue $ 28,103 $ 55,487 $ 83,590 

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2019
Discontinued Operations [Abstract]
Schedule Of Discontinued Operations Balance Sheet	  September 30, December 31,  2019 2018  Accounts receivable, net $ 1 $ 213  Inventories 21 818  Other current assets 217 174  Current assets of discontinued operations 239 1,205   Machinery and equipment - 436  Less: Accumulated depreciation - 126  Net machinery and equipment - 310   Other assets, net - 61  Total assets $ 239 $ 1,576   Accounts payable - 320  Other accrued liabilities 393 16  Current liabilities of discontinued operations 393 336  Net assets (liabilities) $ (154) $ 1,240 
Schedule Of Loss On Sale Of Discontinued Operations	  Cash and cash equivalents $ 5  Accounts receivable, net 72  Write-down of inventory to net realizable value 278  Write-down of property, plant and equipment to salvage value 298  Other assets and liabilities, net 71  Realized loss on foreign currency 280  Net assets disposed 1,004  Additional disposal costs, net 112  Loss on disposal of discontinued operations $ 1,116 
Summary Of Results Of Discontinued Operations	  Three Months Ended Nine Months Ended  September 30, 2019 September 30, 2018 September 30, 2019 September 30, 2018  Revenue, net $ - $ 568 $ 1,068 $ 2,067  Cost of goods sold - 373 667 1,296  Gross profit - 195 401 771  Sales and marketing - 225 314 706  General and administrative - 311 684 1,005  Total operating expenses - 536 998 1,711  Other income, net - 42 - 70  Loss from discontinued operations, net of taxes $ - $ (299) $ (597) $ (870) 

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Summary Of Data By Industry Segment	      For the Three Months Ended September 30, 2019 Body Worn Devices Hearing Health DTEC Total  Revenue, net $ 25,383 $ 1,510 $ 26,893  Income (loss) from continuing operations before income taxes and discontinued operations 750 (953) (203)  Depreciation and amortization 712 108 820  Capital expenditures 1,374 54 1,428   For the Nine Months Ended September 30, 2019 Body Worn Devices Hearing Health DTEC Total  Revenue, net $ 80,924 $ 4,876 $ 85,800  Impairment loss - (3,765) (3,765)  Income (loss) from continuing operations before income taxes and discontinued operations 5,106 (7,603) (2,497)  Depreciation and amortization 2,210 238 2,448  Capital expenditures 3,651 136 3,787       For the Three Months Ended September 30, 2018 Body Worn Devices Hearing Health DTEC Total  Revenue, net $ 28,076 $ 1,490 $ 29,566  Income (loss) from continuing operations before income taxes and discontinued operations 3,146 (1,041) 2,105  Depreciation and amortization 642 55 697  Capital expenditures 1,884 4 1,888   For the Nine Months Ended September 30, 2018 Body Worn Devices Hearing Health DTEC Total  Revenue, net $ 78,263 $ 5,327 $ 83,590  Income (loss) from continuing operations before income taxes and discontinued operations 7,899 (1,992) 5,907  Depreciation and amortization 1,952 155 2,107  Capital expenditures 3,426 70 3,496   The following table summarizes the identifiable assets (excluding goodwill) and goodwill by industry segment as of the following dates :      September 30, December 31,  2019 2018  Body Worn Devices:  Identifiable assets (excluding goodwill) $ 103,158 $ 97,725  Goodwill 9,551 9,551  Hearing Health DTEC:  Identifiable assets (excluding goodwill) 2,732 5,139  Goodwill - 1,257 

Geographic Information (Tables)

Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Geographical Distribution Of Long-Lived Assets, Net	   September 30, December 31,  2019 2018  United States $ 12,264 $ 10,065  Singapore 1,311 1,240  Other 83 117  Consolidated $ 13,658 $ 11,422 
Geographical Distribution Of Net Sales	   Three Months Ended Nine Months Ended  Net Revenue to Geographical Areas September 30, 2019 September 30, 2018 September 30, 2019 September 30, 2018  United States $ 22,483 $ 25,157 $ 71,059 $ 70,871  Europe 1,248 1,500 4,480 4,163  Asia 2,780 2,472 9,508 7,639  All other countries 382 437 753 917  Consolidated $ 26,893 $ 29,566 $ 85,800 $ 83,590 

Investment In Partnerships (Tab

Investment In Partnerships (Tables)	9 Months Ended
	Sep. 30, 2019
Investment In Partnerships [Abstract]
Investments in Partnerships	  September 30, December 31,  2019 2018  Investment in Signison $ 1,246 $ 865  Investment in and cash advance for Soundperience - 1,022  Other 163 204  Total $ 1,409 $ 2,091 

Investment Securities (Tables)

Investment Securities (Tables)	9 Months Ended
	Sep. 30, 2019
Investments Securities [Abstract]
Summary Of Maturity Dates Of Investments	   The maturity dates of our investments as of September 30, 2019 are as follows:  Less than one year 1-5 years Total  Commercial Paper Original Maturities of 91 Days or More $ 6,824 $ - $ 6,824  US Government Agencies - 1,900 1,900  Corporate Notes and Bonds 13,491 11,864 25,355  Total Investments $ 20,315 $ 13,764 $ 34,079 

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2019
Inventories [Abstract]
Schedule Of Inventories	   Raw materials Work-in process Finished products and components Total  September 30, 2019  Domestic $ 11,579 $ 3,103 $ 405 $ 15,087  Foreign 2,315 368 113 2,796  Total $ 13,894 $ 3,471 $ 518 $ 17,883   December 31, 2018  Domestic $ 10,657 $ 2,484 $ 1,583 $ 14,724  Foreign 2,671 653 115 3,439  Total $ 13,328 $ 3,137 $ 1,698 $ 18,163 

Other Assets, Net (Tables)

Other Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2019
Other Assets, Net [Abstract]
Schedule Of Other Assets, Net	  September 30, December 31,  2019 2018  Fitting Software $ 3,679 $ -  NXP Tech 1,964 2,259  Other 553 1,168  Total $ 6,196 $ 3,427 

Goodwill And Intangible Assets

Goodwill And Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets [Abstract]
Schedule Of Goodwill	  Carrying amount at December 31, 2018 $ 10,808  Impairment of goodwill of Hearing Help Express (1,257)  Carrying amount at September 30, 2019 $ 9,551 
Summary of Intangible Assets	  Carrying amount at December 31, 2018 $ 2,585  Amortization of intangible assets of Hearing Help Express (77)  Impairment of intangible assets of Hearing Help Express (2,508)  Carrying amount at September 30, 2019 $ - 

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Summary Of Lease Costs By Type	  Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019  Lease cost  Finance lease cost:  Amortization of right-of-use assets $ 27 $ 76  Interest on lease liabilities 3 8   Operating lease cost* 462 1,379  Variable lease cost** 138 417  Total lease cost $ 630 $ 1,880   *Operating lease cost excludes $0 and $86 related to discontinued operations of the UK for the three and nine months ended September 30, 2019, respectively.  **Variable lease costs consist primarily of taxes, insurance, and common area or other maintenance costs for our domestic and foreign building leases, excluding approximately $0 and $11 related to discontinued operations of the UK for the three and nine months ended September 30, 2019, respectively. 
Maturities Of Lease Liabilities	  Operating Leases Financing Leases Total  2019 $ 503 $ 29 $ 532  2020 1,919 105 2,024  2021 1,588 31 1,619  2022 1,023 3 1,026  2023 416 - 416  2024 and thereafter 93 - 93  Total lease payments 5,542 168 5,710  Less: Interest (456) (5) (461)  Present value of lease liabilities $ 5,086 $ 163 $ 5,249 

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2019
Income Taxes [Abstract]
Domestic And Foreign Income Taxes (Benefits)	   Three Months Ended Nine Months Ended  September 30, 2019 September 30, 2018 September 30, 2019 September 30, 2018  United States $ (261) $ 1,575 $ (3,015) $ 4,876  Singapore (90) 378 131 724  Indonesia 18 18 58 60  Germany 130 134 329 247  Income (loss) from continuing operations before income taxes and discontinued operations $ (203) $ 2,105 $ (2,497) $ 5,907 

Shareholders' Equity And Stoc_2

Shareholders' Equity And Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Shareholders' Equity And Stock-Based Compensation [Abstract]
Summary Of Stock Option Activity	  Outstanding Awards Stock Option Weighted-Average Exercise Price (a) Aggregate Intrinsic Value  Stock Options RSUs Total   Outstanding at December 31, 2018 830 98 928 $ 6.25  Forfeited, cancelled or expired (3) - (3) 6.42  Granted - 79 79 -  Exercised or vested (79) (49) (128) 4.87   Outstanding at September 30, 2019 748 128 876 $ 6.39 $ 12,241   Exercisable at September 30, 2019 670 - 670 $ 6.30 $ 8,799   Available for future grant at December 31, 2018 249   Available for future grant at September 30, 2019 183   (a) The weighted average exercise price calculation does not include outstanding RSUs 

Income Per Share (Tables)

Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Income Per Share [Abstract]
Reconciliation Between Basic And Diluted Earnings Per Share	   Three Months Ended Nine Months Ended  September 30, 2019 September 30, 2018 September 30, 2019 September 30, 2018  Numerator:  Income (loss) from continuing operations before discontinued operations $ (290) $ 2,202 $ (2,831) $ 5,549  Loss on disposal of discontinued operations (Note 3) - - (1,116) -  Loss from discontinued operations, net of income taxes (Note 3) - (299) (597) (870)  Net income (loss) $ (290) $ 1,903 $ (4,544) $ 4,679   Denominator:  Basic – weighted shares outstanding 8,764 7,825 8,738 7,249  Weighted shares assumed upon exercise of stock awards - 997 - 1,111  Diluted – weighted shares outstanding 8,764 8,822 8,738 8,360   Basic income (loss) per share attributable to IntriCon shareholders:  Continuing operations $ (0.03) $ 0.28 $ (0.32) $ 0.77  Discontinued operations - (0.04) (0.20) (0.12)  Net income (loss) per share: $ (0.03) $ 0.24 $ (0.52) $ 0.65   Diluted income (loss) per share attributable to IntriCon shareholders:  Continuing operations $ (0.03) $ 0.25 $ (0.32) $ 0.66  Discontinued operations - (0.03) (0.20) (0.10)  Net income (loss) per share: $ (0.03) $ 0.22 $ (0.52) $ 0.56 

Revenue By Market (Tables)

Revenue By Market (Tables)	9 Months Ended
	Sep. 30, 2019
Revenue By Market [Abstract]
Schedule Of Net Revenue By Market	   Timing of revenue recognition for the three months ended September 30, 2019:  Products and services transferred at point in time Products and services transferred over time Total  Medical Biotelemetry:  Diabetes $ - $ 15,723 $ 15,723  Other Medical - 3,376 3,376  Hearing Health:  Value Based DTEC 1,510 - 1,510  Value Based ITEC 2,443 - 2,443  Legacy OEM 2,405 - 2,405  Professional Audio Communications: 1,436 - 1,436  Total Net Revenue $ 7,794 $ 19,099 $ 26,893   Timing of revenue recognition for the nine months ended September 30, 2019:   Products and services transferred at point in time Products and services transferred over time Total  Medical Biotelemetry:  Diabetes $ - $ 50,837 $ 50,837  Other Medical - 9,947 9,947  Hearing Health:  Value Based DTEC 4,876 - 4,876  Value Based ITEC 7,419 - 7,419  Legacy OEM 7,749 - 7,749  Professional Audio Communications: 4,972 - 4,972  Total Net Revenue $ 25,016 $ 60,784 $ 85,800   Timing of revenue recognition for the three months ended September 30, 2018:   Products and services transferred at point in time Products and services transferred over time Total  Medical Biotelemetry:  Diabetes $ - $ 16,662 $ 16,662  Other Medical - 2,694 2,694  Hearing Health:  Value Based DTEC 1,490 - 1,490  Value Based ITEC 3,660 - 3,660  Legacy OEM 3,056 - 3,056  Professional Audio Communications: 2,004 - 2,004  Total Net Revenue $ 10,210 $ 19,356 $ 29,566   Timing of revenue recognition for the nine months ended September 30, 2018:   Products and services transferred at point in time Products and services transferred over time Total  Medical Biotelemetry:  Diabetes $ - $ 47,531 $ 47,531  Other Medical - 7,956 7,956  Hearing Health:  Value Based DTEC 5,327 - 5,327  Value Based ITEC 8,923 - 8,923  Legacy OEM 8,500 - 8,500  Professional Audio Communications: 5,353 - 5,353  Total Net Revenue $ 28,103 $ 55,487 $ 83,590 

Changes In Accounting Policies

Changes In Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
ROU asset	$ 4,749
Lease liability	$ 5,086
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
ROU asset		$ 6,000
Lease liability		$ 6,000

Discontinued Operations (Narrat

Discontinued Operations (Narrative) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Discontinued Operations, Disposed of by Sale [Member]
Disposal loss after write-down of assets	$ 1,004

Discontinued Operations (Schedu

Discontinued Operations (Schedule Of Discontinued Operations Balance Sheet) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets of discontinued operations	$ 239	$ 1,205
Current liabilities of discontinued operations	393	336
Discontinued Operations, Disposed of by Sale [Member]
Accounts receivable, net	1	213
Inventories	21	818
Other current assets	217	174
Current assets of discontinued operations	239	1,205
Machinery and equipment		436
Less: Accumulated depreciation		126
Net machinery and equipment		310
Other assets, net		61
Total assets	239	1,576
Accounts payable		320
Other accrued liabilities	393	16
Current liabilities of discontinued operations	393	336
Net assets (liabilities)	$ (154)	$ 1,240

Discontinued Operations (Sche_2

Discontinued Operations (Schedule Of Loss On Sale Of Discontinued Operations) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Loss on disposal of discontinued operations	$ 1,116
Discontinued Operations, Disposed of by Sale [Member]
Cash and cash equivalents	5
Accounts receivable, net	72
Write-down of inventory to realizable value	278
Write-down of property, plant and equipment to salvage value	298
Other assets and liabilities, net	71
Realized loss on foreign currency	280
Net assets disposed	1,004
Additional disposal costs, net	112
Loss on disposal of discontinued operations	$ 1,116

Discontinued Operations (Summar

Discontinued Operations (Summary Of Results Of Discontinued Operations) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Loss from discontinued operations, net of taxes	$ (299)	$ (597)	$ (870)
Discontinued Operations, Disposed of by Sale [Member]
Revenue, net	568	1,068	2,067
Cost of goods sold	373	667	1,296
Gross profit	195	401	771
Sales and marketing	225	314	706
General and administrative	311	684	1,005
Total operating expenses	536	998	1,711
Other income, net	42		70
Loss from discontinued operations, net of taxes	$ (299)	$ (597)	$ (870)

Segment Reporting (Narrative) (

Segment Reporting (Narrative) (Details)	9 Months Ended
	Sep. 30, 2019segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Reporting (Summary Of D

Segment Reporting (Summary Of Data By Industry Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Segment Reporting Information [Line Items]
Revenue, net	$ 26,893	$ 29,566	$ 85,800	$ 83,590
Impairment loss			(3,765)
Income (loss) from continuing operations before income taxes and discontinued operations	(203)	2,105	(2,497)	5,907
Depreciation and amortization	820	697	2,448	2,107
Capital expenditures	1,428	1,888	3,787	3,496
Goodwill	9,551		9,551		$ 10,808
Body Worn Devices [Member]
Segment Reporting Information [Line Items]
Revenue, net	25,383	28,076	80,924	78,263
Income (loss) from continuing operations before income taxes and discontinued operations	750	3,146	5,106	7,899
Depreciation and amortization	712	642	2,210	1,952
Capital expenditures	1,374	1,884	3,651	3,426
Identifiable assets (excluding goodwill)	103,158		103,158		97,725
Goodwill	9,551		9,551		9,551
Hearing Health DTEC [Member]
Segment Reporting Information [Line Items]
Revenue, net	1,510	1,490	4,876	5,327
Impairment loss			(3,765)
Income (loss) from continuing operations before income taxes and discontinued operations	(953)	(1,041)	(7,603)	(1,992)
Depreciation and amortization	108	55	238	155
Capital expenditures	54	$ 4	136	$ 70
Identifiable assets (excluding goodwill)	$ 2,732		$ 2,732		5,139
Goodwill					$ 1,257

Geographic Information (Narrati

Geographic Information (Narrative) (Details) - customer	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Net Revenue [Member]
Revenue, Major Customer [Line Items]
Number of customers	1	1	1	1
Percentage of risk	59.00%	56.00%	59.00%	57.00%
Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Number of customers			2		2
Percentage of risk			43.00%		52.00%
Contract Assets [Member]
Revenue, Major Customer [Line Items]
Number of customers			1		1
Percentage of risk			84.00%		78.00%

Geographic Information (Geograp

Geographic Information (Geographical Distribution Of Long-Lived Assets, Net) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	$ 13,658	$ 11,422
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	12,264	10,065
Singapore [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	1,311	1,240
Other Geographical [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	$ 83	$ 117

Geographic Information (Geogr_2

Geographic Information (Geographical Distribution Of Net Sales) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	$ 26,893	$ 29,566	$ 85,800	$ 83,590
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	22,483	25,157	71,059	70,871
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	1,248	1,500	4,480	4,163
Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	2,780	2,472	9,508	7,639
All Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	$ 382	$ 437	$ 753	$ 917

Investment In Partnerships (Nar

Investment In Partnerships (Narrative) (Details) - EUR (€) € in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2019	Dec. 31, 2018	Sep. 30, 2019
Soundperience [Member]
Schedule of Equity Method Investments [Line Items]
Percentage ownership after transaction		49.00%
Percentage Relinquished After Transaction	49.00%
Payments for Software	€ 1,750
Signison [Member]
Schedule of Equity Method Investments [Line Items]
Equity method, ownership interest			50.00%

Investment In Partnerships (Inv

Investment In Partnerships (Investments in Partnerships) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]
Total	$ 1,409	$ 2,091
Signison [Member]
Schedule of Equity Method Investments [Line Items]
Total	1,246	865
Soundperience [Member]
Schedule of Equity Method Investments [Line Items]
Total		1,022
Other Investment [Member]
Schedule of Equity Method Investments [Line Items]
Total	$ 163	$ 204

Investment Securities (Narrativ

Investment Securities (Narrative) (Details)	9 Months Ended
	Sep. 30, 2019
Maximum [Member]
Cash and Cash Equivalents [Line Items]
Maturities benchmark for determining investment in commercial paper, corporate notes and bonds	2 years

Investment Securities (Summary

Investment Securities (Summary Of Maturity Dates Of Investments) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Less than one year	$ 20,315	$ 38,093
1-5 years	13,764
Total	34,079
US Government Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
1-5 years	1,900
Total	1,900
Commercial Paper Original Maturities of 91 Days or More [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Less than one year	6,824
Total	6,824
Corporate Notes And Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Less than one year	13,491
1-5 years	11,864
Total	$ 25,355

Inventories (Schedule Of Invent

Inventories (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory [Line Items]
Raw materials	$ 13,894	$ 13,328
Work-in process	3,471	3,137
Finished products and components	518	1,698
Total	17,883	18,163
Domestic [Member]
Inventory [Line Items]
Raw materials	11,579	10,657
Work-in process	3,103	2,484
Finished products and components	405	1,583
Total	15,087	14,724
Foreign [Member]
Inventory [Line Items]
Raw materials	2,315	2,671
Work-in process	368	653
Finished products and components	113	115
Total	$ 2,796	$ 3,439

Other Assets, Net (Narrative) (

Other Assets, Net (Narrative) (Details) € in Thousands, $ in Thousands	1 Months Ended	9 Months Ended
	Jan. 31, 2019EUR (€)	Sep. 30, 2019USD ($)	Jan. 31, 2019USD ($)
Other Assets, Net [Line Items]
Period of future quartely installments of non-cash amounts, software capitalization		4 years
Software Purchase, Outstanding Liabilities		$ 1,260
Cash Paid At Closing [Member]
Other Assets, Net [Line Items]
Software, capitalized cost			$ 586
Software, Future Quarterly Installments Next Four Years [Member]
Other Assets, Net [Line Items]
Software, capitalized cost			869
Due In January 2023 [Member]
Other Assets, Net [Line Items]
Software, capitalized cost			533
Software, Value Of Partnership And License Agreement Transferred [Member]
Other Assets, Net [Line Items]
Software, capitalized cost			$ 1,691
Soundperience [Member]
Other Assets, Net [Line Items]
Payments for Software | €	€ 1,750
Percent Of Ownership Interest Transferred	49.00%

Other Assets, Net (Schedule Of

Other Assets, Net (Schedule Of Other Assets, Net) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Other Assets [Line Items]
Other assets, net	$ 6,196	$ 3,427
Fitting Software [Member]
Other Assets [Line Items]
Other assets, net	3,679
NXP Tech [Member]
Other Assets [Line Items]
Other assets, net	1,964	2,259
Other Assets [Member]
Other Assets [Line Items]
Other assets, net	$ 553	$ 1,168

Goodwill And Intanigble Assets

Goodwill And Intanigble Assets (Narrative) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Goodwill and Intangible Assets [Abstract]
Goodwill impairment	$ 1,257
Intangible assets impairment	$ 2,508

Goodwill And Intangible Asset_2

Goodwill And Intangible Assets (Schedule Of Goodwill) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Goodwill and Intangible Assets [Abstract]
Goodwill, Beginning Balance	$ 10,808
Impairment of goodwill of Hearing Help Express	(1,257)
Goodwill, Ending Balance	$ 9,551

Goodwill And Intangible Asset_3

Goodwill And Intangible Assets (Summary Of Intangible Assets) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Goodwill and Intangible Assets [Abstract]
Beginning balance	$ 2,585
Amortization of intangible assets of Hearing Help Express	(77)
Impairment of intangible assets of Hearing Help Express	(2,508)
Ending balance

Leases (Narrative) (Details)

Leases (Narrative) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)item	Dec. 31, 2018USD ($)
Lessee, Lease, Description [Line Items]
Finance Lease, Weighted Average Discount Rate, Percent	5.56%
Finance Lease, Weighted Average Remaining Lease Term	1 year 7 months 6 days
Operating Lease, Weighted Average Discount Rate, Percent	5.25%
Operating Lease, Weighted Average Remaining Lease Term	3 years 3 months 18 days
Future minimum payments, 2019		$ 2,417
Future minimum payments, 2020		2,255
Future minimum payments, 2021		1,689
Future minimum payments, 2022		950
Future minimum payments, 2023		$ 188
ROU asset	$ 4,749
Lease liability	5,086
Non-cash increase of operating lease ROU assets	772
Non-cash increase of lease incentive other assets	150
Non-cash increase of lease liabilities	922
Continuing Operations [Member]
Lessee, Lease, Description [Line Items]
Operating Lease, Payments	1,406
Discontinued Operations [Member]
Lessee, Lease, Description [Line Items]
Operating Lease, Payments	84
Non-Cash Operating Lease Right Of Use Assets And Liabilities Derecognized	$ 761
Minnesota [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities | item	3
Illinois [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities | item	1
Singapore [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities | item	1
Indonesia [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities | item	1
ROU asset	$ 103
Lease liability	$ 72
Germany [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities | item	1
Lease Expiration In 2022 [Member] | Minnesota [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities | item	2
Lease Expiration In 2023 [Member] | Minnesota [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities | item	1
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	5 years

Leases (Summary Of Lease Costs

Leases (Summary Of Lease Costs By Type) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Amortization of right-of-use assets	$ 27	$ 76
Interest on lease liabilities	3	8
Operating lease cost	462	1,379
Variable lease cost	138	417
Total lease cost	630	1,880
Discontinued Operations [Member] | United Kingdom [Member]
Operating lease cost	0	86
Variable lease cost	$ 0	$ 11

Leases (Maturities Of Lease Lia

Leases (Maturities Of Lease Liabilities) (Details) $ in Thousands	Sep. 30, 2019USD ($)
Leases [Abstract]
Operating Leases, 2019	$ 503
Operating Leases, 2020	1,919
Operating Leases, 2021	1,588
Operating Leases, 2022	1,023
Operating Leases, 2023	416
Operating Leases, 2024 and thereafter	93
Operating Leases, Total lease payments	5,542
Operating Leases, Less: Interest	(456)
Operating Leases, Present value of lease liabilities	5,086
Financing Leases, 2019	29
Financing Leases, 2020	105
Financing Leases, 2021	31
Financing Leases, 2022	3
Financing Leases, Total lease payments	168
Financing Leases, Less: Interest	(5)
Finaning Leases, Present value of lease liabilities	163
Leases, Liability Payments Remainder Of Fiscal Year	532
Lease, Liability, Payments, Due Year Two	2,024
Lease, Liability, Payments, Due Year Three	1,619
Lease, Liability, Payments, Due Year Four	1,026
Lease, Liability, Payments, Due Year Five	416
Lease, Liability, Payments, Due after Year Five	93
Lease, Liability, Payments, Due	5,710
Lease, Liability, Undiscounted Excess Amount	(461)
Lease, Liability	$ 5,249

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Taxes [Abstract]
Income tax expense (benefit)	$ 87	$ (97)	$ 334	$ 358

Income Taxes (Domestic And Fore

Income Taxes (Domestic And Foreign Income Taxes (Benefits)) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating Loss Carryforwards [Line Items]
Income (loss) from continuing operations before income taxes and discontinued operations	$ (203)	$ 2,105	$ (2,497)	$ 5,907
United States IRS [Member]
Operating Loss Carryforwards [Line Items]
Income before income taxes, United States	(261)	1,575	(3,015)	4,876
Singapore Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Income before income taxes, Foreign	(90)	378	131	724
Indonesia [Member]
Operating Loss Carryforwards [Line Items]
Income before income taxes, Foreign	18	18	58	60
Federal Ministry Of Finance Germany [Member]
Operating Loss Carryforwards [Line Items]
Income before income taxes, Foreign	$ 130	$ 134	$ 329	$ 247

Shareholders' Equity And Stoc_3

Shareholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock for which awards can be granted	183		183		249
Number of Shares, Awards granted			79
Shares purchased for award	2	1	7	5
Stock option expense	$ 648	$ 358	$ 1,514	$ 1,025
Unrecognized compensation costs related to non-vested awards	2,321		$ 2,321
Unrecognized compensation costs related to non-vested awards, recognition period			1 year 11 months 27 days
Total intrinsic value of options exercised	$ 196		$ 1,609
Maximum number of shares approved under purchase plan	300		300
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Number of Shares, Awards granted	4		79
Weighted average fair value of units granted	$ 19.19		$ 23.83
2006 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock for which awards can be granted	369		369
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of options			10 years

Shareholders' Equity And Stoc_4

Shareholders' Equity And Stock-Based Compensation (Summary Of Stock Option Activity) (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding		928
Number of Shares, Options forfeited, cancelled or expired		(3)
Number of Shares, Awards granted		79
Number of Shares, Awards exercised or vested		(128)
Number of Shares, Outstanding	876	876
Number of Shares, Exercisable	670	670
Number of Shares, Available for future grant at beginning of period		249
Number of Shares, Available for future grant at end of period	183	183
Weighted-average Exercise Price, Outstanding | $ / shares		$ 6.25
Weighted-average Exercise Price, Awards forfeited, cancelled or expired | $ / shares		6.42
Weighted-average Exercise Price, Awards exercised or vested | $ / shares		4.87
Weighted-average Exercise Price, Outstanding | $ / shares	$ 6.39	6.39
Weighted-average Exercise Price, Exercisable | $ / shares	$ 6.30	$ 6.30
Aggregate Intrinsic Value, Outstanding | $	$ 12,241	$ 12,241
Aggregate Intrinsic Value, Exercisable | $	$ 8,799	$ 8,799
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding		830
Number of Shares, Options forfeited, cancelled or expired		(3)
Number of Shares, Awards exercised or vested		(79)
Number of Shares, Outstanding	748	748
Number of Shares, Exercisable	670	670
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding		98
Number of Shares, Awards granted	4	79
Number of Shares, Awards exercised or vested		(49)
Number of Shares, Outstanding	128	128

Income Per Share (Narrative) (D

Income Per Share (Narrative) (Details) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of diluted income per share	755	778
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of diluted income per share	125	125

Income Per Share (Reconciliatio

Income Per Share (Reconciliation Between Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended					9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Per Share [Abstract]
Income (loss) from continuing operations before discontinued operations	$ (290)			$ 2,202		$ (2,831)	$ 5,549
Loss on disposal of discontinued operations (Note 3)						(1,116)
Loss from discontinued operations, net of income taxes (Note 3)				(299)		(597)	(870)
Net income (loss)	$ (290)	$ (5,030)	$ 775	$ 1,903	$ 757	$ (4,544)	$ 4,679
Basic - weighted shares outstanding	8,764			7,825		8,738	7,249
Weighted shares assumed upon exercise of stock awards				997			1,111
Diluted - weighted shares outstanding	8,764			8,822		8,738	8,360
Continuing operations	$ (0.03)			$ 0.28		$ (0.32)	$ 0.77
Discontinued operations				(0.04)		(0.20)	(0.12)
Net income (loss) per share:	(0.03)			0.24		(0.52)	0.65
Continuing operations	(0.03)			0.25		(0.32)	0.66
Discontinued operations				(0.03)		(0.20)	(0.10)
Net income (loss) per share:	$ (0.03)			$ 0.22		$ (0.52)	$ 0.56

Related-Party Transactions (Nar

Related-Party Transactions (Narrative) (Details) € in Thousands, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2019EUR (€)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)
Related Party Transaction [Line Items]
Legal services and costs | $		$ 63	$ 238	$ 169	$ 413
Soundperience [Member]
Related Party Transaction [Line Items]
Payments for Software | €	€ 1,750
Percent Of Ownership Interest Transferred	49.00%

Revenue By Market (Schedule Of

Revenue By Market (Schedule Of Net Revenue By Market) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue, Major Customer [Line Items]
Total Net Revenue	$ 26,893	$ 29,566	$ 85,800	$ 83,590
Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	7,794	10,210	25,016	28,103
Products and Services Transferred over Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	19,099	19,356	60,784	55,487
Medical Biotelemetry, Diabetes [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	15,723	16,662	50,837	47,531
Medical Biotelemetry, Diabetes [Member] | Products and Services Transferred over Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	15,723	16,662	50,837	47,531
Medical Biotelemetry, Other Medical [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	3,376	2,694	9,947	7,956
Medical Biotelemetry, Other Medical [Member] | Products and Services Transferred over Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	3,376	2,694	9,947	7,956
Hearing Health Value Based DTEC [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,510	1,490	4,876	5,327
Hearing Health Value Based DTEC [Member] | Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,510	1,490	4,876	5,327
Hearing Health Value Based ITEC [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	2,443	3,660	7,419	8,923
Hearing Health Value Based ITEC [Member] | Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	2,443	3,660	7,419	8,923
Legacy OEM [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	2,405	3,056	7,749	8,500
Legacy OEM [Member] | Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	2,405	3,056	7,749	8,500
Professional Audio Communications [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,436	2,004	4,972	5,353
Professional Audio Communications [Member] | Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	$ 1,436	$ 2,004	$ 4,972	$ 5,353